Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 330 results for antibiotics

  1. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

  2. Prophylactic antibiotics for preventing exacerbations: - What is the long-term clinical and cost effectiveness of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    Prophylactic antibiotics for preventing exacerbations: - What is the long-term clinical and cost effectiveness of prophylactic...

  3. Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of seasonal versus continuous prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of seasonal versus continuous prophylactic...

  4. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

  5. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (HTG253)

    Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.

  6. Cystic fibrosis: adherence to therapy (chronic pseudomonas acquisition) (IND294)

    This indicator covers normative adherence to nebulised therapy in cystic fibrosis for patients with chronic pseudomonas acquisition. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  7. Cystic fibrosis: adherence to therapy (IND293)

    This indicator covers patient adherence to nebulised therapy in cystic fibrosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  8. Association between treating infections in pregnancy and rates of cerebral palsy:- What is the association between different antibiotic regimes to treat genito-urinary and respiratory tract infections in pregnant women and subsequent rates of cerebral palsy in children?

    and rates of cerebral palsy:- What is the association between different antibiotic regimes to treat genito-urinary and respiratory tract...

  9. Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

    Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.

  10. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  11. Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

  12. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  13. What is the effectiveness and cost effectiveness of intravenous compared with oral antibiotics for preventing postnatal infections after birth with forceps or ventouse?

    effectiveness and cost effectiveness of intravenous compared with oral antibiotics for preventing postnatal infections after birth with...

  14. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.